undamentalytics Newsletter
Sign in

Crispr Therapeutics AG balance sheet

At the end of fiscal 2025, Crispr Therapeutics AG had total assets of $2.27bn, total liabilities of $343m and shareholders' equity of $1.92bn. It held $348m in cash against $0 of debt: net cash of $348m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents1563162404579441,169923212389298348192
Receivables03300000200250—
Total current assets1573202484669881,7172,4181,8531,9081,9371,9862,285
Total assets1593452714891,0671,8282,7522,2432,2302,2422,2652,556
Accounts payable252569152738151121
Deferred revenue (current)———0121044163
Total current liabilities10221528579412012110988149141
Long-term debt38—————————0587
Total debt38—000000000600
Total liabilities1241128497127164352368347310343908
Shareholders' equity−292331883929391,6642,3991,8751,8831,9321,9221,648
Non-controlling interests and other (assets − liabilities − equity)64———————————
Net debt (negative = net cash)−118−316−240−457−944−1,169−923−212−389−298−348408
Shares outstanding6m—41m52m61m74m77m79m80m86m96m97m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABEO vs CRSPCRSP vs JANXCRSP vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Crispr Therapeutics AG's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Crispr Therapeutics AG.